Sandi has more than 20 years of executive and entrepreneurial experience in the pharmaceutical and biotechnology industry, specializing in oncology, hematology and infectious diseases. Her global business experience encompasses executive management, commercial operations, strategic business development, licensing, mergers and acquisitions, franchise development, market access and health policy influence, marketing and sales. 


In her role of consultant, Sandi has championed the successful development of strategic clinical and commercialization plans that led to successful product regulatory approvals (FDA, EMEA, and international markets), label expansions, life cycle management, licensing deals and corporate M&As. 


Sandi began her pharmaceutical career with Eli Lilly's Hospital Division and was later on, one of the first hires for the Bristol Myers Oncology Franchise.  Sandi spent 16 years with BMS in varying positions of increasing global responsibility with P&L responsibilities exceeding $2B. BMS has one of the most successful Oncology franchises in the pharmaceutical industry built on licensing and commercialization strategies.  Following her years at BMS Sandi spent two years at Amgen focusing on market expansion of the Neupogen Franchise.


Sandi earned her Bachelor of Science Honors degree from the University of Manitoba and her Masters of Business Administration from the Canadian Institute of Management.  She is the recipient of several outstanding service awards, honors and distinctions including being a guest lecturer at Wharton School of Business.